Table 1.
Baseline patient characteristics.
| N = 110 (%) | |
|---|---|
| Age (years) | 58 (20–77) |
| Male gender | 98 (89.1) |
| Etiology | |
| HBV | 99 (90.0) |
| HCV | 2 (1.8) |
| Alcohol | 4 (3.6) |
| Unknown | 5 (4.5) |
| ECOG PS | |
| 0–1 | 96 (87.3) |
| 2 | 14 (12.7) |
| BCLC stage | |
| C | 110 (100.0) |
| Child–Pugh class | |
| A | 88 (80.0) |
| B | 22 (20.0) |
| ALBI grade | |
| 1 | 24 (21.8) |
| 2 | 69 (62.7) |
| 3 | 17 (15.5) |
| Macrovascular invasion | |
| Yes | 51 (46.4) |
| No | 59 (53.6) |
| Extrahepatic metastasis | |
| Yes | 104 (94.5) |
| No | 6 (5.5) |
| AFP, median (range), ng/ml | 475.6 (1.6–503,168) |
| <400 | 52 (47.3) |
| ⩾400 | 54 (49.1) |
| Unknown | 4 (3.6) |
| Previous systemic treatment lines | |
| 1 | 2 (1.8) |
| 2 | 18 (16.4) |
| ⩾3 | 90 (81.8) |
| Previous treatments | |
| Liver transplantation | 9 (8.2) |
| Surgical resection | 47 (42.7) |
| TACE | 85 (77.3) |
| RFA | 9 (8.2) |
| SBRT | 46 (41.8) |
| Previous systemic treatment | |
| Sorafenib | 104 (94.5) |
| Lenvatinib | 26 (23.6) |
| Regorafenib | 91 (82.7) |
| Ramucirumab | 2 (1.8) |
| Nivolumab | 82 (74.5) |
| Atezolizumab + bevacizumab | 10 (9.1) |
| Durvalumab | 2 (1.8) |
| Pembrolizumab | 3 (2.7) |
| Doxorubicin + cisplatin | 3 (2.7) |
ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; PS, performance status; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization.
Data are presented as n (%) or median (range).